Cytosorbents Co. (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $8.00, for a total value of $80,000.00. Following the completion of the transaction, the chief financial officer now directly owns 268,870 shares in the company, valued at $2,150,960. The transaction was disclosed in a filing with the SEC, which is available at this link.
CTSO stock opened at $7.35 on Friday. Cytosorbents Co. has a 12-month low of $3.30 and a 12-month high of $8.25. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.54 and a current ratio of 2.64.
Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The firm had revenue of $4.65 million for the quarter, compared to the consensus estimate of $4.56 million. Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. research analysts anticipate that Cytosorbents Co. will post -0.47 earnings per share for the current fiscal year.
Several research firms recently issued reports on CTSO. ValuEngine raised Cytosorbents from a “hold” rating to a “buy” rating in a research report on Tuesday, April 3rd. HC Wainwright set a $14.00 price objective on Cytosorbents and gave the company a “buy” rating in a research report on Friday, March 9th. Cowen set a $9.00 price objective on Cytosorbents and gave the company a “buy” rating in a research report on Thursday, March 8th. Maxim Group set a $12.00 price objective on Cytosorbents and gave the company a “buy” rating in a research report on Friday, March 9th. Finally, B. Riley reaffirmed a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents in a research report on Thursday, January 25th. Six research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $11.05.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Cytosorbents by 182.3% during the 4th quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock valued at $136,000 after buying an additional 13,515 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Cytosorbents during the 4th quarter valued at $146,000. Fortaleza Asset Management Inc. lifted its holdings in shares of Cytosorbents by 60.9% during the 4th quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock valued at $244,000 after buying an additional 14,240 shares during the period. Wealthcare Advisory Partners LLC bought a new position in shares of Cytosorbents during the 3rd quarter valued at $365,000. Finally, BlueCrest Capital Management Ltd bought a new position in shares of Cytosorbents during the 4th quarter valued at $396,000. 10.84% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/cytosorbents-co-ctso-cfo-sells-80000-00-in-stock.html.
Cytosorbents Company Profile
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.